Premium
Plasma P‐tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease
Author(s) -
Chong Joyce R.,
Ashton Nicholas J.,
Karikari Thomas K.,
Tanaka Tomotaka,
Saridin Francis N.,
Reilhac Anthonin,
Robins Edward G.,
Nai YingHwey,
Vrooman Henri,
Hilal Saima,
Zetterberg Henrik,
Blennow Kaj,
Lai Mitchell K.P.,
Chen Christopher P.
Publication year - 2021
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.12332
Subject(s) - concomitant , atrophy , cohort , medicine , dementia , hippocampal formation , amyloid (mycology) , biomarker , pathology , alzheimer's disease , oncology , disease , chemistry , biochemistry
There is increasing evidence that phosphorylated tau (P‐tau181) is a specific biomarker for Alzheimer's disease (AD) pathology, but its potential utility in non‐White patient cohorts and patients with concomitant cerebrovascular disease (CeVD) is unknown. Methods Single molecule array (Simoa) measurements of plasma P‐tau181, total tau, amyloid beta (Aβ)40 and Aβ42, as well as derived ratios were correlated with neuroimaging modalities indicating brain amyloid (Aβ+), hippocampal atrophy, and CeVD in a Singapore‐based cohort of non‐cognitively impaired (NCI; n = 43), cognitively impaired no dementia (CIND; n = 91), AD ( n = 44), and vascular dementia (VaD; n = 22) subjects. Results P‐tau181/Aβ42 ratio showed the highest area under the curve (AUC) for Aβ+ (AUC = 0.889) and for discriminating between AD Aβ+ and VaD Aβ− subjects (AUC = 0.903). In addition, P‐tau181/Aβ42 ratio was associated with hippocampal atrophy. None of the biomarkers was associated with CeVD. Discussion Plasma P‐tau181/Aβ42 ratio may be a noninvasive means of identifying AD with elevated brain amyloid in populations with concomitant CeVD.